{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:20:22Z","timestamp":1783340422056,"version":"3.54.6"},"posted":{"date-parts":[[2025,9,19]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":40,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Community-wide screening is a crucial strategy to end tuberculosis (TB), but a common concern is potential harm from overtreatment following false positive diagnoses. However, current reference standards determining test performance have limitations, with implications for prevalence thresholds and treatment decisions for community-wide screening.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We estimated coverage of community-wide screening at a prevalence threshold of 0.5% (current global standard), 0.25%, and 0.1% for adult pulmonary TB. We considered test performance for Xpert Ultra against different reference standards (sputum culture, plus clinical evaluation, plus disease progression within two years). Potential harm was estimated through disability adjusted life years (DALYs) incurred or averted by treatment. We report net specificity, positive predictive value (PPV), the ratio of false positives to true positives, and DALYs averted for (non-)treatment based on different reference standards.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A lower threshold would increase screening coverage from the current 42% to 84% (0.25% threshold) and 89% (0.1% threshold) of the global TB burden. In a population of 100,000 with 0.5% prevalence, specificity was 99.5% for community screening, but increased to 99.7% using disease progression as reference standard, with PPV increasing from 45 to 66%. In addition, estimated harm of withholding appropriate treatment was approximately 1,200 times higher compared to providing inappropriate treatment, with treatment initiation after a positive Xpert Ultra increasing overall DALYs averted (median 5,977 versus 3,750).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>The benefit of TB treatment following a positive molecular test in community-wide screening likely outweighs the harm associated with possible overtreatment, supporting expanding coverage of simplified community-wide screening.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Brief summary<\/jats:title>\n                  <jats:p>A concern with community-wide tuberculosis screening is the potential for overtreatment. We evaluated diagnostic reference standards and relative health costs of (non-)treatment, finding that after a positive molecular test, the benefit of initiating tuberculosis treatment likely outweighs its harm.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.09.18.25335917","type":"posted-content","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T14:50:19Z","timestamp":1758293419000},"source":"Crossref","is-referenced-by-count":1,"title":["Do no harm - re-evaluating the risks of overtreatment in community-wide tuberculosis screening"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4132-7467","authenticated-orcid":false,"given":"Rein M.G.J.","family":"Houben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara D.","family":"Veeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Schwalb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Grint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinout","family":"van Crevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025092204351050000_2025.09.18.25335917v1.1","unstructured":"World Health Organisation. Global Tuberculosis Report [Internet]. Geneva: World Health Organisation; 2024. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024"},{"key":"2025092204351050000_2025.09.18.25335917v1.2","doi-asserted-by":"crossref","unstructured":"Esmail H , Miller C , Falzon D , de Vries G , Chijioke-Akaniro O , Horton KC , et al. Scaling-up symptom-agnostic, community-wide screening towards global tuberculosis elimination: opportunities, challenges and lessons from history. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2025 Mar 9;107875.","DOI":"10.1016\/j.ijid.2025.107875"},{"issue":"5","key":"2025092204351050000_2025.09.18.25335917v1.3","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies","volume":"119","year":"1979","journal-title":"Am Rev Respir Dis"},{"issue":"10","key":"2025092204351050000_2025.09.18.25335917v1.4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.5588\/ijtld.22.0216","article-title":"Use of chest radiography screening for TB: a re-evaluation of the Kol\u00edn study","volume":"26","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"2025092204351050000_2025.09.18.25335917v1.5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1353\/hah.2009.0007","article-title":"\u2018A Scandal Which Must be Corrected\u2019: Reconsidering the Success of the Australian Tuberculosis Campaign","volume":"11","year":"2009","journal-title":"Health Hist"},{"issue":"11","key":"2025092204351050000_2025.09.18.25335917v1.6","doi-asserted-by":"crossref","first-page":"e1004448","DOI":"10.1371\/journal.pmed.1004448","article-title":"Impact of active case finding for tuberculosis with mass chest X-ray screening in Glasgow, Scotland, 1950\u20131963: An epidemiological analysis of historical data","volume":"21","year":"2024","journal-title":"PLOS Med"},{"key":"2025092204351050000_2025.09.18.25335917v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902129"},{"issue":"1","key":"2025092204351050000_2025.09.18.25335917v1.8","first-page":"150","article-title":"What if they don\u2019t have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis","volume":"68","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025092204351050000_2025.09.18.25335917v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30067-6"},{"key":"2025092204351050000_2025.09.18.25335917v1.10","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.221802"},{"key":"2025092204351050000_2025.09.18.25335917v1.11","unstructured":"Veeken LD , Schwalb A , Horton KC , Koesoemadinata RC , Alisjahbana B , van Crevel R , et al. Mind the clinic-community gap: how concerned should we be about false positive test results in mass tuberculosis screening? J Infect Dis. 2025 May 23;jiaf268."},{"key":"2025092204351050000_2025.09.18.25335917v1.12","first-page":"CD009593","article-title":"Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis","volume":"2","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025092204351050000_2025.09.18.25335917v1.13","doi-asserted-by":"crossref","unstructured":"Rockman L , Abdulgader SM , Minnies S , Palmer Z , Naidoo CC , Venter R , et al. Oral washes and tongue swabs for Xpert MTB\/RIF Ultra-based tuberculosis diagnosis in people with and without the ability to make sputum. Clin Infect Dis Off Publ Infect Dis Soc Am. 2025 July 18;ciaf397.","DOI":"10.21203\/rs.3.rs-6225530\/v1"},{"key":"2025092204351050000_2025.09.18.25335917v1.14","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01463-09"},{"key":"2025092204351050000_2025.09.18.25335917v1.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058195"},{"key":"2025092204351050000_2025.09.18.25335917v1.16","doi-asserted-by":"crossref","unstructured":"Niemand N , Rooney JA , Malatesta S , Rawoot N , Bouton TC , Ragan EJ , et al. Contamination rates in serially sampled sputum specimens obtained during tuberculosis treatment to capture culture conversion. Microbiol Spectr. 2025 Aug 29;e0096925.","DOI":"10.1101\/2025.03.26.25324668"},{"key":"2025092204351050000_2025.09.18.25335917v1.17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1824"},{"key":"2025092204351050000_2025.09.18.25335917v1.18","unstructured":"Sossen B , Richards AS , Heinsohn T , Frascella B , Balzarini F , Oradini-Alacreu A , et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Respir Med [Internet]. 2023 Mar 23 [cited 2023 Mar 24]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213260023000978"},{"issue":"12","key":"2025092204351050000_2025.09.18.25335917v1.19","first-page":"1619","article-title":"Epidemiological impact of mass tuberculosis screening: a 2-year follow-up after a national prevalence survey","volume":"16","year":"2012","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"key":"2025092204351050000_2025.09.18.25335917v1.20","doi-asserted-by":"crossref","unstructured":"Sung J , Nantale M , Nalutaaya A , Bich\u00e9 P , Mukiibi J , Akampurira J , et al. The long-term risk of tuberculosis among individuals with Xpert Ultra \u201ctrace\u201d screening results: a longitudinal follow-up study [Internet]. medRxiv; 2025 [cited 2025 Apr 15]. p. 2025.03.20.25324205. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2025.03.20.25324205v1","DOI":"10.1101\/2025.03.20.25324205"},{"key":"2025092204351050000_2025.09.18.25335917v1.21","doi-asserted-by":"crossref","unstructured":"Saavedra B , Mambuque E , Nguenha D , Gomes N , Munguambe S , Garc\u00eda JI , et al. Performance of Xpert MTB\/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding. Eur Respir J [Internet]. 2021 Dec 23 [cited 2025 Apr 22];58(6). Available from: https:\/\/publications.ersnet.org\/content\/erj\/58\/6\/2100257","DOI":"10.1183\/13993003.00257-2021"},{"key":"2025092204351050000_2025.09.18.25335917v1.22","unstructured":"GTB-TME. 2024 GTB report dataset - age-sex disaggregated country incidence [Internet]. [cited 2025 Sept 16]. Available from: https:\/\/github.com\/GTB-TME\/gtbreport2024\/blob\/main\/disaggregation\/output\/A_country_incidence_disaggregate d_age_sex_num.Rdata"},{"key":"2025092204351050000_2025.09.18.25335917v1.23","doi-asserted-by":"crossref","unstructured":"Veeken LD , Horton KC , Houben RMGJ. Authors\u2019 response to \u2018TB prevalence in people tested is a strong predictor of Xpert specificity in community and risk group screening\u2019. J Infect Dis. 2025 Aug 9;jiaf419.","DOI":"10.1093\/infdis\/jiaf419"},{"key":"2025092204351050000_2025.09.18.25335917v1.24","doi-asserted-by":"crossref","unstructured":"McCreesh N , Govender I , Grant AD , Khan PY . TB prevalence in people tested is a strong predictor of Xpert specificity in community and risk group screening. J Infect Dis. 2025 Aug 7;jiaf418.","DOI":"10.1093\/infdis\/jiaf418"},{"issue":"9","key":"2025092204351050000_2025.09.18.25335917v1.25","doi-asserted-by":"crossref","first-page":"e0005050","DOI":"10.1371\/journal.pgph.0005050","article-title":"Potential impact, costs, and benefits of population-wide screening interventions for tuberculosis in Viet Nam: A mathematical modelling study","volume":"5","year":"2025","journal-title":"PLOS Glob Public Health"},{"key":"2025092204351050000_2025.09.18.25335917v1.26","unstructured":"Paton NI , Cousins C , Sari IP , Burhan E , Ng NK , Dalay VB , et al. Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial. Lancet Infect Dis. 2025 May 22;S1473-3099(25)00151-3."},{"key":"2025092204351050000_2025.09.18.25335917v1.27","doi-asserted-by":"crossref","unstructured":"Kendall EA , Dowdy DW . The health impact of identifying a person with tuberculosis through systematic screening. Lancet Infect Dis. 2025 May 20;S1473-3099(25)00214-2.","DOI":"10.1016\/S1473-3099(25)00214-2"},{"issue":"1","key":"2025092204351050000_2025.09.18.25335917v1.28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/EDE.0000000000001418","article-title":"The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease","volume":"33","year":"2022","journal-title":"Epidemiology"},{"issue":"11","key":"2025092204351050000_2025.09.18.25335917v1.29","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","article-title":"Disability weights for the Global Burden of Disease 2013 study","volume":"3","year":"2015","journal-title":"Lancet Glob Health"},{"key":"2025092204351050000_2025.09.18.25335917v1.30","unstructured":"World Health Organisation. C. Target product profiles for tuberculosis screening tests [Internet]. Geneva; 2025. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/382179\/9789240113572-eng.pdf"},{"issue":"12","key":"2025092204351050000_2025.09.18.25335917v1.31","doi-asserted-by":"crossref","first-page":"e1679","DOI":"10.1016\/S2214-109X(21)00367-3","article-title":"Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025092204351050000_2025.09.18.25335917v1.32","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0423"},{"issue":"4","key":"2025092204351050000_2025.09.18.25335917v1.33","first-page":"582","article-title":"Health-state utilities in liver disease: a systematic review","volume":"28","year":"2008","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"2025092204351050000_2025.09.18.25335917v1.34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017601"},{"key":"2025092204351050000_2025.09.18.25335917v1.35","doi-asserted-by":"crossref","unstructured":"Ragonnet R , Flegg JA , Brilleman SL , Tiemersma EW , Melsew YA , McBryde ES , et al. Revisiting the Natural History of Pulmonary Tuberculosis: a Bayesian Estimation of Natural Recovery and Mortality rates. Clin Infect Dis [Internet]. 2020 [cited 2020 Aug 10]; Available from: https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciaa602\/5882189","DOI":"10.1101\/729426"},{"key":"2025092204351050000_2025.09.18.25335917v1.36","doi-asserted-by":"crossref","unstructured":"Velen K , Shingde RV , Ho J , Fox GJ . The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis. Eur Respir J [Internet]. 2021 Dec 9 [cited 2025 Aug 26];58(6). Available from: https:\/\/publications.ersnet.org\/content\/erj\/58\/6\/2100266","DOI":"10.1183\/13993003.00266-2021"},{"key":"2025092204351050000_2025.09.18.25335917v1.37","doi-asserted-by":"crossref","first-page":"e82469","DOI":"10.7554\/eLife.82469","article-title":"Estimating the contribution of subclinical tuberculosis disease to transmission: An individual patient data analysis from prevalence surveys","volume":"12","year":"2023","journal-title":"eLife"},{"key":"2025092204351050000_2025.09.18.25335917v1.38","doi-asserted-by":"crossref","unstructured":"Dalmat RR , Visek C , Budiawan E , Stein G , Nalutaaya A , Mukiibi J , et al. Cumulative TB disease burden following sputum Xpert Ultra \u2018Trace\u2019 results in clinical settings: Results from a multi-site observational clinical study [Internet]. medRxiv; 2025 [cited 2025 Sept 16]. p. 2025.07.14.25331384. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2025.07.14.25331384v1","DOI":"10.1101\/2025.07.14.25331384"},{"key":"2025092204351050000_2025.09.18.25335917v1.39","doi-asserted-by":"crossref","unstructured":"Shapiro AE , Dalmat RR , Mukwatamundu J , Kamoga C , Ngwane MW , Steadman A , et al. Diagnostic accuracy of tongue swab testing in persons with sputum Xpert Ultra Trace results [Internet]. medRxiv; 2025 [cited 2025 Sept 16]. p. 2025.07.15.25331566. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2025.07.15.25331566v1","DOI":"10.1101\/2025.07.15.25331566"},{"key":"2025092204351050000_2025.09.18.25335917v1.40","doi-asserted-by":"crossref","unstructured":"Grint DJ , White RG , Churchyard G , Fiore-Gartland A , Rangaka MX , Garcia-Basteiro AL , et al. Imprecision in tuberculosis infection outcomes; implications for non-inferiority vaccine trials [Internet]. medRxiv; 2025 [cited 2025 June 26]. p. 2025.06.19.25329919. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2025.06.19.25329919v1","DOI":"10.1101\/2025.06.19.25329919"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.09.18.25335917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:46:19Z","timestamp":1768509979000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.09.18.25335917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1101\/2025.09.18.25335917","relation":{},"subject":[],"published":{"date-parts":[[2025,9,19]]},"subtype":"preprint"}}